Production (Stage)
CorMedix Inc.
CRMD
$12.36
$0.100.82%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 41,186.87% | 2,108.49% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 41,186.87% | 2,108.49% | -- |
| Cost of Revenue | 384.87% | -- | 503,625.00% | 69,810.53% | 37,104.55% |
| Gross Profit | 9,701.11% | -- | 34,873.72% | -1,609.25% | -1,574.77% |
| SG&A Expenses | 33.70% | 63.94% | 102.53% | 106.17% | 89.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.59% | 34.46% | 51.59% | 54.27% | 57.63% |
| Operating Income | 126.49% | 54.34% | -22.27% | -52.31% | -57.89% |
| Income Before Tax | 133.27% | 58.30% | -19.47% | -47.71% | -52.67% |
| Income Tax Expenses | 100.00% | -- | -- | -- | -138.18% |
| Earnings from Continuing Operations | 134.20% | 61.31% | -15.97% | -43.93% | -51.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 134.20% | 61.31% | -15.97% | -43.93% | -51.16% |
| EBIT | 126.49% | 54.34% | -22.27% | -52.31% | -57.89% |
| EBITDA | 127.35% | 54.90% | -22.02% | -52.27% | -58.05% |
| EPS Basic | 126.09% | 64.53% | 6.43% | -8.92% | -17.14% |
| Normalized Basic EPS | 125.43% | 61.88% | 3.60% | -11.77% | -18.02% |
| EPS Diluted | 124.32% | 64.53% | 6.43% | -8.92% | -17.14% |
| Normalized Diluted EPS | 123.64% | 61.88% | 3.60% | -11.77% | -18.02% |
| Average Basic Shares Outstanding | 12.17% | 15.76% | 23.14% | 32.80% | 29.91% |
| Average Diluted Shares Outstanding | 13.89% | 15.76% | 23.14% | 32.80% | 29.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |